IRIS UniCatt

Sora', Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.856
AS - Asia 4.434
EU - Europa 4.230
SA - Sud America 1.056
AF - Africa 142
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 5
Totale 14.733
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.720
SG - Singapore 2.133
DE - Germania 1.255
CN - Cina 1.180
BR - Brasile 876
SE - Svezia 729
IT - Italia 713
FR - Francia 276
GB - Regno Unito 262
IE - Irlanda 249
VN - Vietnam 209
IN - India 205
UA - Ucraina 199
ID - Indonesia 178
FI - Finlandia 153
RU - Federazione Russa 123
TR - Turchia 74
KR - Corea 71
AR - Argentina 66
BD - Bangladesh 66
HK - Hong Kong 62
CA - Canada 53
MX - Messico 49
NL - Olanda 48
IQ - Iraq 40
PL - Polonia 34
AT - Austria 32
JP - Giappone 32
CI - Costa d'Avorio 29
BE - Belgio 28
EC - Ecuador 28
IR - Iran 27
ZA - Sudafrica 25
ES - Italia 24
UZ - Uzbekistan 23
CZ - Repubblica Ceca 22
CO - Colombia 19
KE - Kenya 18
MA - Marocco 18
SA - Arabia Saudita 18
VE - Venezuela 17
EG - Egitto 16
PK - Pakistan 16
UY - Uruguay 13
JO - Giordania 12
LT - Lituania 12
PY - Paraguay 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
CL - Cile 10
HU - Ungheria 10
PE - Perù 10
AZ - Azerbaigian 9
IL - Israele 9
NP - Nepal 9
AL - Albania 8
RO - Romania 8
DZ - Algeria 7
LB - Libano 7
TN - Tunisia 7
AU - Australia 6
DO - Repubblica Dominicana 6
JM - Giamaica 6
PA - Panama 6
EE - Estonia 5
ET - Etiopia 5
PH - Filippine 5
SN - Senegal 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
BZ - Belize 4
OM - Oman 4
PT - Portogallo 4
TW - Taiwan 4
AM - Armenia 3
AO - Angola 3
BA - Bosnia-Erzegovina 3
GE - Georgia 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LI - Liechtenstein 3
MD - Moldavia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
QA - Qatar 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BH - Bahrain 2
BO - Bolivia 2
CR - Costa Rica 2
GA - Gabon 2
GR - Grecia 2
HN - Honduras 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
MY - Malesia 2
AF - Afghanistan, Repubblica islamica di 1
BW - Botswana 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
Totale 14.708
Salva come PNG Salva come JPEG
Città #
Singapore 956
Chandler 639
Ashburn 564
Dublin 245
Beijing 242
Hefei 200
Woodbridge 179
Jakarta 160
Los Angeles 160
Jacksonville 157
San Mateo 137
Rome 129
Dearborn 125
Nanjing 112
Wilmington 112
Munich 107
Houston 98
Milan 97
New York 96
Fairfield 90
Hyderabad 87
Ann Arbor 84
Frankfurt am Main 83
Seattle 74
Boston 73
Cattolica 71
Chicago 71
Moscow 71
Ho Chi Minh City 67
Seoul 67
Florence 63
São Paulo 62
Princeton 58
Hanoi 57
Hong Kong 57
Redmond 57
Dallas 56
Helsinki 54
Kent 54
Buffalo 53
Nürnberg 53
Lancaster 52
Nanchang 51
Redwood City 50
The Dalles 49
Marseille 46
Lawrence 41
Bremen 39
Izmir 35
Lappeenranta 35
Santa Clara 34
Abidjan 29
Brussels 28
Tokyo 28
London 27
Rio de Janeiro 27
Atlanta 25
Kunming 25
Warsaw 24
Brooklyn 23
Dhaka 23
Norwalk 23
Nuremberg 23
Belo Horizonte 22
Tianjin 22
Boardman 21
Toronto 20
Stockholm 19
Tashkent 19
Düsseldorf 18
Phoenix 18
Pune 18
San Francisco 18
Shanghai 18
Guangzhou 17
Leawood 17
Turku 17
Cambridge 16
Campinas 16
Hangzhou 16
Mountain View 16
Porto Alegre 16
Vienna 16
Auburn Hills 15
Baghdad 15
Brno 15
Nairobi 15
Orem 15
Philadelphia 15
Shenyang 15
Amsterdam 14
Curitiba 14
Da Nang 14
Manchester 14
Poplar 14
Bexley 13
Charlotte 13
Fremont 13
Hebei 13
Jiaxing 13
Totale 7.314
Salva come PNG Salva come JPEG
Nome #
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 403
Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis 349
Dasatinib first-line: Multicentric Italian experience outside clinical trials 283
Dasatinib first-line: Multicentric Italian experience outside clinical trials 280
Twenty years of unrestricted hematopoietic stem cell collection and storage: impact of Joint Accreditation Committee International Society for Cellular Therapy Europe standards implementation on stem cell storage policy and resource utilization 274
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome 194
Correlation between paraproteinaemia and viral reactivation after allo-SCT 185
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. 175
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 164
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation 161
Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients 160
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia 158
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 155
Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab. 151
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS 141
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation 140
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration 137
AB0 type does not affect platelet engraftment after autologous peripheral blood stem cell transplant in a series of 249 hematologic patients 137
H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016 136
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 135
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 131
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine 127
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 124
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 124
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 124
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo) 122
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 121
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 120
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 119
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 118
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 117
Non-tunnelled central venous catheters in adult stem cell transplantation recipients: an effective option 114
Twenty years of unrestricted hematopoietic stem cell collection and storage: impact of Joint Accreditation Committee International Society for Cellular Therapy Europe standards implementation on stem cell storage policy and resource utilization 114
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 113
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 108
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 107
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 107
Unrelated cord blood transplantation and post-transplant cyclophosphamide 103
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 103
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity 102
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 102
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 101
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 100
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 99
the concomitance of lymphoma and breast carcinoma in the bone 99
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study 97
Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study 96
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 96
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 96
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 95
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation 93
Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience 93
Second haploidentical stem cell transplantation for primary graft failure 93
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study 92
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 90
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. 88
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 88
Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up 87
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 86
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 86
Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR) 84
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study 84
Unrelated cord blood transplantation and post-transplant cyclophosphamide 84
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic 83
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 83
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 83
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-t Cells 82
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 82
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 82
Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review 81
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 81
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 81
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 80
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 80
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 80
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 80
allogenic hemopoietic stem cell transplant in patients with acute myeloid leukemia prepared with busulfan and fludarabine or thiotepa busulfan and fludarabine a retrospective study 80
CAR-T treatment is safe and effective in adult patients with Down syndrome and B-cell acute lymphoblastic leukemia (B-ALL) 80
Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry 79
Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party 79
Treatment patterns in patients with chronic-phase chronic myeloid leukaemia in routine clinical practice: The simplicity Italian population 78
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 78
The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity 77
CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation 77
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 77
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 77
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 77
Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience 77
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy 77
Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients 76
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline 76
VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response 76
Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients 75
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 74
Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients 74
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 73
Chlorambucil PLUS Rituximab As FRONT-LINE THERAPY in Elderly or Unfit Patients Affected by B-CELL Chronic Lymphocytic Leukemia: Results of A Single-Centre Retrospective Analysis 73
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 73
next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome -positive acute lymphoblastic leukemia 72
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 72
Totale 11.250
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.643
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.643
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021325 0 0 0 0 0 47 45 13 72 17 113 18
2021/2022916 76 39 34 41 65 24 18 139 49 62 181 188
2022/20232.043 254 244 148 252 209 274 95 150 257 51 82 27
2023/20241.297 42 353 58 88 43 152 98 77 26 69 121 170
2024/20253.255 98 80 217 173 255 117 115 133 435 313 746 573
2025/20263.936 1.115 231 465 740 1.095 290 0 0 0 0 0 0
Totale 14.992